Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s ...

Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi SAN-1.02%decrease; red down pointing triangle posted better-than-expected earnings and sales in the third quarter, ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

They even have a partnership with Sanofi to make a 30-day ... which can lead to other complications if mixed with medications ...

Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...